ATE420945T1 - Chemisch definiertes medium für kultivierte säugerzellen - Google Patents

Chemisch definiertes medium für kultivierte säugerzellen

Info

Publication number
ATE420945T1
ATE420945T1 AT02709335T AT02709335T ATE420945T1 AT E420945 T1 ATE420945 T1 AT E420945T1 AT 02709335 T AT02709335 T AT 02709335T AT 02709335 T AT02709335 T AT 02709335T AT E420945 T1 ATE420945 T1 AT E420945T1
Authority
AT
Austria
Prior art keywords
chemically defined
defined medium
mammal cells
cultured
cultured mammal
Prior art date
Application number
AT02709335T
Other languages
English (en)
Inventor
Chichang Lee
Celia Ly
Gordon Moore
Robert Perkinson
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23024766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE420945(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Inc filed Critical Centocor Inc
Application granted granted Critical
Publication of ATE420945T1 publication Critical patent/ATE420945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02709335T 2001-02-15 2002-02-05 Chemisch definiertes medium für kultivierte säugerzellen ATE420945T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26884901P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
ATE420945T1 true ATE420945T1 (de) 2009-01-15

Family

ID=23024766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02709335T ATE420945T1 (de) 2001-02-15 2002-02-05 Chemisch definiertes medium für kultivierte säugerzellen

Country Status (7)

Country Link
US (1) US6900056B2 (de)
EP (1) EP1360314B1 (de)
JP (2) JP2005505240A (de)
AT (1) ATE420945T1 (de)
CA (1) CA2438148A1 (de)
DE (1) DE60230858D1 (de)
WO (1) WO2002066603A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512538A (ja) * 2001-12-14 2005-05-12 セントカー・インコーポレーテツド 無血清培地中でタンパク質を製造するのに有用なクローン性骨髄腫細胞系
CA2417689C (en) * 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
EP1664283A4 (de) * 2003-09-18 2007-12-26 Raven Biotechnologies Inc Zellkulturmedien
CA2552229C (en) 2003-12-26 2013-03-12 Miho Furue Basal medium for es cell culturing
US20080241925A1 (en) * 2004-09-02 2008-10-02 Angela Paz Judith Cruz Three-Dimensional Self Assembly in Suspension of Adherent Cells
JP4833991B2 (ja) * 2004-11-02 2011-12-07 アレス トレーディング ソシエテ アノニム 哺乳動物細胞のための無血清細胞培養培地
US8273553B2 (en) * 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
WO2007028106A2 (en) 2005-08-31 2007-03-08 Centocor, Inc. Host cell lines for production of antibody constant region with enhanced effector function
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
JP5576115B2 (ja) * 2007-04-26 2014-08-20 中外製薬株式会社 高濃度アミノ酸含有培地を用いた細胞の培養方法
WO2008141207A1 (en) * 2007-05-11 2008-11-20 Amgen Inc. Improved feed media
US7723491B1 (en) 2007-05-25 2010-05-25 Clemson University Methods of isolating specific compounds from supramammary lymph node tissue
DK2250251T3 (en) * 2008-01-09 2018-01-22 Sartorius Stedim Cellca Gmbh Improved culture medium additive and method of using it
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
WO2011069091A1 (en) 2009-12-04 2011-06-09 Boston Biomedical Research Institute, Inc. Method for cloning pluripotent stem cells
PT2563904E (pt) 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
WO2013009648A2 (en) 2011-07-08 2013-01-17 Momenta Pharmaceuticals, Inc. Cell culture process
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US20240052392A1 (en) * 2012-04-24 2024-02-15 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US20150267237A1 (en) * 2012-04-24 2015-09-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
NO2760138T3 (de) * 2012-10-01 2018-08-04
US20140170748A1 (en) * 2012-12-14 2014-06-19 DePuy Synthes Products, LLC Nutrient Enriched Media for hUTC Growth
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
EP2970916B1 (de) 2013-03-13 2021-04-14 Merck Sharp & Dohme Corp. Adaptierte lepidoptera-insektenzellen zur produktion rekombinanter proteine
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP3052640A2 (de) 2013-10-04 2016-08-10 AbbVie Inc. Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015128314A1 (en) 2014-02-27 2015-09-03 F. Hoffmann-La Roche Ag Modulation of cell growth and glycosylation in recombinant glycoprotein production
WO2015137640A1 (ko) * 2014-03-13 2015-09-17 한양대학교 산학협력단 화학 조성 세포 배양 배지 첨가물
KR101714860B1 (ko) 2014-03-13 2017-03-09 한양대학교 산학협력단 화학 조성 세포 배양 배지 첨가물
WO2015148515A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
EP3129463B1 (de) 2014-04-10 2021-05-26 Bayer Healthcare LLC Zellformulierung in pulverform und verfahren zur herstellung von flüssigen zellkulturmedium
WO2016049363A1 (en) 2014-09-24 2016-03-31 Los Alamos National Security, Llc Bio-assessment device and method of making the device
EP3090738A1 (de) * 2015-05-04 2016-11-09 Universidade de Santiago de Compostela Riboflavin zur behandlung ischämischer schlaganfälle und/oder anderer glutamatexzitotoxizität-assoziierter erkrankungen
US20180355304A1 (en) * 2015-12-03 2018-12-13 Merck Patent Gmbh Chemically defined media for the growth or detection of microorganisms
RU2748057C2 (ru) 2016-01-14 2021-05-19 Депуи Синтез Продактс, Инк. Композиция и способы криоконсервации клеток hutc
CA3019753C (en) 2016-04-05 2021-10-26 Pfizer Inc. Cell culture process
JP2020127383A (ja) * 2019-02-08 2020-08-27 学校法人 東洋大学 培養方法、培養装置、廃水処理方法及び廃水処理装置
CA3129732A1 (en) * 2019-02-14 2020-08-20 North Grove Investments, Inc. Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof
CN110241090B (zh) * 2019-05-07 2023-10-13 江苏南农高科技股份有限公司 一种全悬浮细胞培养生产猪伪狂犬病毒抗原的方法
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
JP7822149B2 (ja) 2020-10-02 2026-03-02 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
CN115386534B (zh) * 2022-10-26 2023-02-21 天信和(苏州)生物科技有限公司 利用无血清培养基培养bhk21细胞的方法及其在制备疫苗中的用途
WO2026006162A2 (en) 2024-06-24 2026-01-02 Genentech, Inc. B vitamin modulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205126A (en) * 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
CS262822B1 (en) * 1986-10-03 1989-04-14 Kovar Jan Synthetic medium for the cultivation of myelomic cells
JPH078273A (ja) * 1993-06-14 1995-01-13 Kurabo Ind Ltd 接着性動物細胞の無血清培養法
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
DE69623109T2 (de) * 1996-04-19 2002-12-12 Societe Des Produits Nestle S.A., Vevey Menschliche immortalisierte Colon-Epithelialzellen
EP2243827B2 (de) * 1996-08-30 2017-11-22 Life Technologies Corporation Serumfreies kulturmedium für säugerzellen und seine verwendung
AU4751797A (en) * 1996-10-11 1998-05-11 Life Technologies, Inc. Defined systems for epithelial cell culture and use thereof
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells

Also Published As

Publication number Publication date
EP1360314A4 (de) 2004-08-11
EP1360314B1 (de) 2009-01-14
JP2008178419A (ja) 2008-08-07
EP1360314A2 (de) 2003-11-12
DE60230858D1 (de) 2009-03-05
US20030096402A1 (en) 2003-05-22
WO2002066603A3 (en) 2002-12-19
CA2438148A1 (en) 2002-08-29
US6900056B2 (en) 2005-05-31
WO2002066603A2 (en) 2002-08-29
JP2005505240A (ja) 2005-02-24

Similar Documents

Publication Publication Date Title
DE60230858D1 (de) Chemisch definiertes medium für kultivierte säugerzellen
ATE359358T1 (de) Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
DE60031419D1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
ATE464373T1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
WO2004090096A3 (en) Methods for neural differentiation of embryonic stem cells using protease passaging techniques
EP1860180A4 (de) Verfahren zur amplifikation einer endothelvorläuferzelle in vitro
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
DE60231074D1 (de) Mediumzusätze und medien für tierzellkulturen
TW200736399A (en) Expansion and differentiation of neural stem cells under low oxygen conditions
BRPI0514694A (pt) produção de proteìna de fusão tnfr-ig
NO20064379L (no) Anvendelse av et serumfritt cellekulturmedium for produsjonen av IL-18BP i pattedyrceller
UA92157C2 (ru) Способ продуцирования гормона роста
ATE384120T1 (de) Metallbindende verbindungen und deren verwendung in zusammensetzungen für zellkulturmedien
EP1499710A4 (de) Verfahren zum wachstum von menschlichen bindehautgewebeäquivalenten für die forschung, die klinische augenoberflächentransplantation und die geweberekonstruktion
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
NO20006545D0 (no) Fremgangsmåte for in vitro modning av humane kjönnsceller
DK1651754T3 (da) Myelomcellekultur i transferrinfrit medium med lavt jernindhold
WO2003052064A3 (en) Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
NO20041641L (no) Grise-mastcelle-kulturer og anvendelser derav
AU2003242533A1 (en) Glutamine-free medium
WO2003051720A3 (en) A myeloma cell line useful for manufacturing recombinant proteins in chemically defined media
WO2004053080A3 (en) Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
ATE313622T1 (de) Verfahren zur züchtung von haftenden tierischen zellen
EA200701000A1 (ru) Культуральная среда для клеток млекопитающих, не содержащая сыворотки

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties